| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Oncologia Medica and
1 Medicina Interna, Università di Torino, Azienda Ospedaliera San Luigi, Regione Gonzole 10 10043 Orbassano, Torino, Italy
2 Endocrinologia, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy
3 Istituto di Endocrinologia, Università Cattolica, Policlinico A Gemelli, Roma, Italy
4 Endocrinology and Metabolism Service, Division of Medicine, Hadassah University Hospital, Jerusalem, Israel
5 Oncologia Medica, Istituto Clinico Humanitas, Rozzano, Milano, Italy
6 Oncologia Medica, Istituto Nazionale dei Tumori, Milano, Italy
7 Urologia, Azienda Ospedaliera San Luigi, Orbassano, TO, Italy
8 Dipartimento di Scienze Mediche Chirurgiche, Endocrinologia, Università di Padova, Italy
(Requests for offprints should be addressed to Luigi Dogliotti; Email: luigi.dogliotti{at}unito.it)
To investigate the activity of etoposide, doxorubicin, and cisplatin plus mitotane in the management of advanced adrenocortical carcinoma (ACC) patients, 72 patients with measurable disease not amenable to radical surgery were enrolled in a prospective, multicenter phase II trial. EDP schedule (etoposide 100 mg/m2 on days 5–7, doxorubicin 20 mg/m2 on days 1 and 8, and cisplatin 40 mg/m2 on days 1 and 9) was administered intravenously every 4 weeks. Concomitantly, patients were given up to 4 g/day of oral mitotane. Five patients achieved a complete response and 30 a partial response, for an overall response rate of 48.6% (95% CI: 37.1–60.3). Median time to progression in responding patients was 18 months. The EDP regimen was well tolerated, leukopenia being the dose limiting toxicity. One toxic related death due to septic shock, however, was registered. Radical surgical resection of residual disease after chemotherapy was performed in 10 patients. The overall survival of patients attaining a disease free status (clinical complete responders+radically resected) was significantly higher than that of patients with partial response or no response (P<0.002). Androgen secretion was associated with long survival, while glucocorticoid secretion was associated with poor prognosis both in univariate and multivariate analysis. In conclusion, EDP plus mitotane is an active and manageable combination scheme for ACC patients. Surgical resection of residual disease subsequent to chemotherapy leads to a more favourable outcome. The natural history of the disease is significantly influenced by the secretory status of the tumor.
This article has been cited by other articles:
|
|
 |
|
  S. Chalasani, H. S. Vats, T. K. Banerjee, and A. K. McKenzie Metastatic Virilizing Adrenocortical Carcinoma: A Rare Case of Cure with Surgery and Mitotane Therapy Clin. Med. Res., June 1, 2009; 7(1-2): 48 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-O. Lee, K.-W. Lee, C.-J. Kim, Y. J. Kim, H. E. Lee, H. Kim, J. H. Kim, S.-M. Bang, J.-S. Kim, and J. S. Lee Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report Jpn. J. Clin. Oncol., March 1, 2009; 39(3): 183 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rodriguez-Galindo, G. Zambetti, and R. C. Ribeiro Epidemiology, Clinical Characteristics, and Treatment of Childhood Adrenocortical Tumors ASCO Educational Book, January 1, 2009; 2009(1): 625 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Q. Almeida, M. C. B. V. Fragoso, C. F. P. Lotfi, M. G. Santos, M. Y. Nishi, M. H. S. Costa, A. M. Lerario, C. C. Maciel, G. E. Mattos, A. A. L. Jorge, et al. Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3524 - 3531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Quinkler, S. Hahner, S. Wortmann, S. Johanssen, P. Adam, C. Ritte, C. Strasburger, B. Allolio, and M. Fassnacht Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2057 - 2062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P. A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, et al. Adjuvant Mitotane Treatment for Adrenocortical Carcinoma N. Engl. J. Med., June 7, 2007; 356(23): 2372 - 2380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Libe, A. Fratticci, and J. Bertherat Adrenocortical cancer: pathophysiology and clinical management Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ohwada, M. Izumi, S. Kawate, K. Hamada, H. Toya, N. Togo, J. Horiguchi, Y. Koibuchi, T. Takahashi, and M. Yamada Surgical Outcome of Stage III and IV Adrenocortical Carcinoma Jpn. J. Clin. Oncol., February 2, 2007; (2007) hyl127v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Assie, G. Antoni, F. Tissier, B. Caillou, G. Abiven, C. Gicquel, S. Leboulleux, J.-P. Travagli, C. Dromain, X. Bertagna, et al. Prognostic Parameters of Metastatic Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 148 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Kirschner Paradigms for adrenal cancer: think globally, act locally. J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4250 - 4252. [Full Text] [PDF]
|
|
|
|
|
|
G. Abiven, J. Coste, L. Groussin, P. Anract, F. Tissier, P. Legmann, B. Dousset, X. Bertagna, and J. Bertherat Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2650 - 2655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Allolio and M. Fassnacht Adrenocortical Carcinoma: Clinical Update J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2027 - 2037. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
